Yifang Biotech announced that in the first half of 2026, it achieved operating income of 533.192 million yuan, an increase of 178.23% over the previous year; net loss attributable to shareholders of listed companies of 137 million yuan, net loss of 119 million yuan for the same period last year; and net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 144 million yuan. R&D investment accounted for 346.43% of revenue, a year-on-year decrease of 256.05 percentage points. Basic earnings per share - $0.24. As of the end of the reporting period, the total assets of the company were 1,522 billion yuan, and the net assets attributable to shareholders of listed companies were 1,411 billion yuan.

Yifang Biotech announced that in the first half of 2026, it achieved operating income of 533.192 million yuan, an increase of 178.23% over the previous year; net loss attributable to shareholders of listed companies of 137 million yuan, net loss of 119 million yuan for the same period last year; and net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 144 million yuan. R&D investment accounted for 346.43% of revenue, a year-on-year decrease of 256.05 percentage points. Basic earnings per share - $0.24. As of the end of the reporting period, the total assets of the company were 1,522 billion yuan, and the net assets attributable to shareholders of listed companies were 1,411 billion yuan.